Korean American Society in Biotech and Pharmaceuticals
재미한인제약인협회

KASBP SAN FRANCISCO

KASBP-SF SYMPOSIUM 2026

January 10th, 2026 9:00 AM - 6:00 PM

Embassy Suites by Hilton San Francisco Airport Oyster Point
250 Gateway Blvd, South San Francisco, CA 94080

Symposium Schedule

Time	Jan 10th, 2026 (Saturday)
8:30	Registration with light breakfast
Opening and Congratulatory Remarks / Facilitator: OhKyu Yoon	
9:00	• President, KASBP-SF : OhKyu Yoon • Vice President, KASBP : Min-Kyu Cho • Consul General, San Francisco Embassy : Jung-Taek Lim • COO/President, LigaChem Biosciences : Sejin Park
Session 1: Targeted Delivery of Small Molecule Drugs / Chair: Soojin Kim	
9:20	Nam-Gu Her (AimedBio) ***"Global Trends in ADCs and AimedBio's Strategic Development Approach"***
9:55	Hyunsun Jo (Pin Therapeutics) ***"Advancing Cancer Therapy with a CK1α-Selective MGD: A New Approach for p53 Activation in Hematological and Solid Tumors"***
10:30	Coffee Break
10:45	Jeiwook Chae (Ligachem Biosciences) ***"Driving the Future of ADC Innovation: Industry-Leading Science, Platform Technologies, and Advancing Clinical Pipeline Shaping Next-Generation ADCs"***
Sponsor Presentation I / Moderator: Sungjin Lee	
11:20	Yejin Lee (Yuhan)
11:35	Jin Seok Jeong (DongA ST)
11:50	Nam-Gu Her (AimedBio)
12:00	Group Photo, Photographer - Sooha Ryu
12:10	Lunch
1:00	Roundtable Networking / Moderator: Sungjin Lee
Sponsor Presentations II / Moderator: Yumee Kim	
2:30	Joosung Yang (Samyang Biopharm)
2:40	Sejin Park (LigaChem Biosciences)
3:00	KASBP-SF LigaChem Fellowship Award
Session 2: Where Business Meets Science / Chair: Hyang Jo	
3:10	Sehyun Jason Kim (Meck & Co.) ***"From Data to Deals: Navigating the I&I Landscape"***
3:25	Ted Jeong (Adelphi Ventures) ***"Beyond the Headwinds: VC Priorities and the Strategic Shift for Korean Biotech Funding"***
3:40	Kelly Kim (Olix Pharmaceuticals) ***"Earning the Yes: Turning Science into Deals"***
3:55	Coffee Break
4:10	Panel discussion: Agatha Lee (moderator) Sehyun Jason Kim, Ted Jeong, Kelly Kim, Elizabeth Cho-Fertikh
4:55	Closing Remarks - KASBP-SF President : OhKyu Yoon
5:00	Social Networking, sponsored by LigaChemBio

Platinum Sponsor

LigaChemBio
X
KASBP-SF

LCB
LigaChemBio

Recruit LigaChemBio

리가켐바이오사이언스에서 미래를 함께할 글로벌 인재를 찾고 있습니다

KASBP-SF 인재분들의 많은 지원을 바랍니다

채용포지션

ADC센터 Project Leader, 연구원
Innovation / New Modality 센터 Bio 연구원
Innovation / New Modality 센터 Chemistry 연구원
신약연구소 Translational Research 연구원
개발본부 Translational Research 센터장 : Head of Translational Research Center
중개의약팀 : Teams leader & members of Translational Medicine Team
비임상약리팀 : Team leader & members of Non-Clinical Pharmacology Team

Compensation

단독 사용가능한 아파트 및 오피스텔 제공, 항공료, 이사비 등 국내 복귀 비용 지원
자녀 학자금 지원
장기근속/우수성과 스톡옵션/RSU 제도 운영, 국내 최고수준의 기술이전 포상제도 운영
국내·외 학회참석, 온라인 교육 지원
사내식당 운영 : 조·중·석식 무료 제공
경조사비 제공, 종합건강검진(본인 및 가족), 장기근속 포상, 법인콘도 이용 등

지원방법

회사 채용 홈페이지(www.ligachembio.com)
문의 : 경영기획팀 채용담당자 (oyj@ligachembio.com)

채용홈페이지 QR

KASBP-SF LigaChem Fellowship Award

Tumor and Microenvironment Co-evolution in Metastatic Triple-negative Breast Cancer During Immunotherapy

Seongyeol Park[1], Manon de Graaf[2], Artem Lomakin[3], Zhicheng Ma[1], Noah Greenwald[4,5], Lise Mangiante[1], Clemens Weiss[1], Brennan Simon[5], Mikaela Ribi[6], Kathleen Houlahan[1], Jolene Ranek[4], Aziz Khan[1], Michael Angelo[4], Marleen Kok[2], Christina Curtis[1,3,5,7]

1. Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA
2. Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
3. Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA
4. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
5. Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA
6. Department of Chemistry, Stanford University School of Humanities and Sciences, Stanford, CA, USA
7. Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

Cancer cells constantly interact with the surrounding microenvironment. Understanding the co-evolution of tumors and their microenvironments is crucial for cancer biology and immunotherapy. Metastatic triple-negative breast cancer (mTNBC) is the most aggressive type of breast cancer with a poor prognosis. While recent immunotherapy trials for mTNBC have shown promise, the reasons for limited and variable responses remain unclear.

To investigate this, we developed a multimodal, longitudinal dataset combining spatial proteomics (MIBI 40-plex protein) and spatial transcriptomics (CosMx, 6k-plex) from mTNBC patients enrolled in the TONIC trial of nivolumab following induction therapy (NCT02499367). We collected 400 tissue samples from 110 patients, including the primary tumor and metastatic sites (e.g., lymph nodes, liver, and skin), including both pre- and on-treatment biopsies, enabling in-depth analysis of tumor-microenvironment interactions and evolution during immunotherapy.

These analyses revealed relationships between tumor cell states and their spatial niches. For example, tumor inflammatory responses are associated with immune infiltration, while EMT-related changes are associated with the tumor-dominant niche. Copy-number alterations, inferred from expression data, showed a homogeneous pattern despite the heterogeneous cellular states and spatial niches. Notably, responders exhibited more organized and consistent directional changes in tumor and microenvironment features before and after immunotherapy compared to non-responders. This comprehensive, multi-dimensional approach advances our understanding of tumor-immune dynamics in mTNBC and suggests strategies to enhance immunotherapy outcomes.

Speakers' Bio

Dr. Nam-Gu Her is the CEO of AimedBio Inc., a biotech spun out from Samsung Medical Center that focuses on developing next-generation Antibody-based therapeutics including ADC and bispecific antibodies. Before becoming CEO, he served as the first Head of R&D of Aimed Bio, leading the establishment of Aimed Bio's early R&D programs. Prior to joining Aimed Bio, Dr. Her led both the Antibody Discovery Team and Drug Screening Team at Samsung Medical Center, where he directed translational oncology research and therapeutic target validation projects. He has closed multiple global licensing and R&D collaboration deals and secured over 10 government grants as Principal Investigator. Dr. Her has extensive experience in biotech innovation, operations, and business development, and is currently leading Aimed Bio's preparation for its KOSDAQ IPO in December 2025.

Global Trends in ADCs and AimedBio's Strategic Development Approach

Antibody–Drug Conjugates (ADCs) are reshaping the oncology landscape, combining the precision of antibodies with the potency of small-molecule therapeutics. More than 300 ADC programs are currently in clinical development, and over the past few years, the field has witnessed major M&A transactions, landmark licensing deals, and significant commercial successes across multiple tumor types. Market forecasts continue to strengthen, driven by promising clinical data and rapid advances in payload chemistry, linker design, and target discovery.

This presentation will review the recent trends in ADC development and licensing deals, illustrating how the global ADC ecosystem is evolving both scientifically and strategically.

It will also introduce Aimed Bio's science-driven, clinically-aligned R&D model, which has enabled the company to establish itself as one of the emerging Korean biotech through multiple global partnerships and, its strong scientific and translational strengths.

Hyunsun Jo received his B.S and Ph.D. degrees in Biological Sciences from Seoul National University and performed post-doctoral research at Gladstone Institute at UCSF. He has spent the past 14 years as a biotech entrepreneur in the biotech industry, focusing on targeted protein degradation, where he has led new E3 ligase ligand discovery and conducted target validation across a wide range of proteins.

Advancing Cancer Therapy with a CK1α-Selective MGD: A New Approach for p53 Activation in Hematological and Solid Tumors

CK1α is a member of casein kinase 1 (CK1) family, a multifunctional serine/threonine kinase conserved in eukaryotes from yeast to humans. Substrates of CK1α includes various proteins important in cancer and regulates multiple survival pathways such as p53 , Wnt, autophagy and NF-κB signaling pathways. In particular, CK1α serves as an upstream regulator of p53 pathway through regulation of MDM2 and MDMX and degradation of CK1α may prevent MDM2 and/or MDMX mediated inactivation of p53 function, thus facilitate cell death. We identified a potent and selective molecular glue degrader (MGD) of CK1α and it could reactivate the tumor suppressor protein p53, thereby providing a novel treatment strategy for both solid and hematological cancers. Given the low frequency of TP53 mutations in adenoid cystic carcinoma (ACC) and acute myeloid leukemia (AML), targeting CK1α offers a promising approach to restore p53 function.

Dr. Jeiwook (Jei) Chae is the Executive Vice President and Chief Business Development Officer at LigaChem Biosciences (LCB), where he leads the company's global business development and R&D strategy and external partnership. He has played a central role in establishing LCB as a global ADC innovator, securing multi-billion-dollar partnerships with major pharmaceutical companies including Johnson & Johnson, Amgen, Ono Pharmaceutical, and advancing LCB's clinical-stage and late-stage best-in-class and first-in-class ADC programs.

Previously, Dr. Chae served as Head of R&D at Bioneer, leading new drug development including siRNA therapeutics and RNAi pipeline initiatives. Before entering industry, he conducted postdoctoral research at Harvard University on intercellular RNAi signaling and earned his Ph.D. from the University of Virginia, building expertise in preclinical disease models, oncology pharmacology, and translational research.

Driving the Future of ADC Innovation: Industry-Leading Science, Platform Technologies, and a Advancing Clinical Pipeline Shaping Next-Generation ADCs

Antibody–drug conjugates (ADCs) are rapidly evolving worldwide, driven by innovations that improve stability, tumor selectivity, and resistance profiles. LigaChem Biosciences (LCB), a strong research-based global biotechnology company, has been recognized with a World ADC Award for its next-generation engineering platform. LCB's ConjuALL™ technology, integrating site-specific conjugation, a plasma-stable proprietary linker, and tumor-activated payloads, enables homogeneous ADCs and highly selective intratumoral release, resulting in a markedly improved therapeutic index.

LCB has established itself as a major global ADC innovator, securing over 13 licensing deals with a cumulative value exceeding $8 billion, including strategic partnerships with leading pharmaceutical companies such as Johnson & Johnson, Amgen, Ono, and others.

LCB's clinical-stage and late-stage ADC programs, spanning both best-in-class and first-in-class modalities, highlight the platform's broad applicability and competitive strength. This presentation will highlight the mechanisms behind LCB's award-winning technology, emerging clinical insights, and forward-looking innovations in platform technologies including new payload architectures — reflecting LCB's commitment to driving the future of novel ADC technologies and offering an exciting environment for world-class scientific talent.

Dr. Sehyun (Jason) Kim is Director of Business Development & Licensing at Merck & Co., where he leads late-stage Immunology Search & Evaluation and has led multiple transactions, most recently Merck's acquisition of Verona Pharma. Previously, he led external innovation and BD at ABL Bio, contributing to out-licensing ABL301 to Sanofi and advancing partnerships across oncology and neurology. Earlier, Dr. Kim was a Senior Scientific Researcher in Immunology at Genentech and held academic research roles at NYU School of Medicine, Rockefeller University, and the University of Oklahoma Health Sciences Center. He earned a PhD in Cell Biology from the University of Oklahoma Health Sciences Center and an MBA from the Haas School of Business at UC Berkeley.

From Data to Deals: Navigating the I&I Landscape

The immunology and inflammation (I&I) ecosystem is crowded, fast-moving, and increasingly shaped by data-driven decision-making. This session presents a structured framework for assessing the I&I landscape from a Business Development perspective. The talk will outline how to scope therapeutic segments, map mechanisms of action, and benchmark assets across clinical phase, differentiation, and commercial potential. "*Winners and losers*" will be assessed using objective signals—clinical effect size, safety/tolerability, trial design rigor, regulatory path clarity, launch readiness, and payer receptivity—integrated into a consistent valuation view. Emphasis is placed on how valuation is built from data analysis, including scenario modeling (peak sales, probability of technical and regulatory success), sensitivity to label/line of therapy, and risk-adjusted NPV with competitive timing overlays. The importance of competitive intelligence will be highlighted, showing how CI informs "*threat*" mapping, counter-positioning, and deal timing. The session concludes with a forward look at future players—emerging modalities, next-gen targets, and platform contenders—and practical implications for portfolio strategy, search and evaluation, and partnering.



Ted (Tae Heum) Jeong is the Founder and Managing Partner of healthcare-focused Adelphi Ventures. A seasoned venture capitalist and corporate finance expert with over 25 years of experience, he previously co-founded and was Managing Partner at Kensington-SV Global Innovations. Dr. Jeong has a proven track record, having led or participated in over 60 investments with successful returns at KSV and Hyundai Ventures. His international experience includes numerous financing deals in the U.S. and Asia. As a science-oriented entrepreneur, he grew Rexahn Pharmaceuticals from its inception to a NASDAQ-listed public company. As a financial executive at Rexahn and Clene Nanomedicine, he raised over $200 million for oncology and CNS therapeutics. Currently, he serves as Executive Chairman of OmicInsight Corporation and Nurron Pharmaceuticals, and has held board positions at Neurobo Pharmaceuticals and Shuttle Pharmaceuticals. He also serves as advisor to Healthcare & Biopharma CVC Fund Investment Committee of Lotte Holdings. He holds B.S. and M.S. degrees in chemistry from POSTECH, an M.S. in finance from Johns Hopkins University, and a Doctorate in Management from the University of Maryland.

Beyond the Headwinds: VC Priorities and the Strategic Shift for Korean Biotech Funding

The global fundraising environment for biotech currently presents significant challenges due to macroeconomic headwinds and valuation corrections, especially for Korean startups seeking international capital. This presentation, delivered from a Venture Capitalist's perspective, moves beyond general advice to dissect the concrete priorities of U.S. and global VCs in the current market. The session will highlight key shifts in investor priorities, including the importance of M&A driven by upcoming patent cliffs, the rise of China as a competitor, and the influence of AI transformation. Attendees will gain a thorough understanding of the current VC mindset, focusing on practical strategies to thrive in this competitive arena. Emphasis will be placed on aligning innovation with investor expectations and leveraging emerging trends to secure sustainable capital. Case studies will illustrate how successful biopharma companies utilized distinct growth strategies to secure major returns. The goal is to provide practical strategies for mitigating valuation risks and positioning startups for their next round of global capital.

Ms. Kelly Kim serves as Director of Business Development at OliX Pharmaceuticals, where she leads the company's global partnership strategy and oversees key external collaborations. Since joining OliX, she has successfully executed major licensing deals with Hansoh Pharma, Eli Lilly and Company, and L'Oréal, each built upon the company's core platforms. In her role, Ms. Kim manages licensing transactions, investment initiatives, and other strategic partnerships that have been pivotal to OliX's growth and global positioning in the RNA therapeutics field.

With a strong foundation in pharmaceutical sciences, operational leadership, and cross-functional communication, Ms. Kim is dedicated to advancing collaborations that translate scientific innovation into meaningful healthcare solutions. She earned her B.S. in Pharmaceutical Sciences from the University of California, Irvine.

Earning the Yes: Turning Science into Deals

In today's biotech landscape, scientific innovation is only the starting point. Turning that innovation into impactful partnerships requires strategic positioning, clear value articulation, and long-term relationship building, where Business Development plays a critical role. Lessons from a range of collaborations, spanning early discovery alliances in new geographies to clinically driven and cross-industry initiatives, demonstrate that success depends as much on timing, communication, and mutual trust as it does on science itself.

Earning a "*yes*" ultimately comes down to the ability to navigate these factors seamlessly. It is about understanding when and how to engage, building trust that endures beyond a single transaction, and aligning internal and external stakeholders around a shared vision. Thoughtful BD strategy, when executed this way, can transform scientific strength into meaningful and lasting deals.

Elizabeth Cho-Fertikh, Ph.D. is Co-founder and Managing Director at the healthcare investor group, MEDA Angels and as Managing Partner at MEDA Ventures. The MEDA Angels Fund has fully deployed its Fund 1 and collectively with its SPVs, has a portfolio of 23 companies, 2 exits and 0 shutdowns. Fund 2 will continue under MEDA Ventures, investing in early stage MedTech and Life Science companies and is utilizing a novel funding vehicle employing a 3rd party validated AI-predictive platform and an insurance element to protect against downside risk to life science investing while increasing the upside. She has nearly 30 years of experience in drug development & clinical trials at biotechs & startups (oncology, infectious diseases, neurodegenerative diseases), regulatory affairs, grants administration & private markets. She is also the host of the healthcare segment of the Resilient Alpha podcast, interviewing headliners, financial and investment leaders. Launched in mid-2025, the podcast has received 100K+ views, annualizing at 2 million views across multiple social media channels. The podcast is an extension of one of the largest family office networks in the US, Ivyfon. Dr. Cho-Fertikh serves on Boards/Advisory Boards of startups and can frequently be found on the speaking, judging and mentoring circuits of the startup ecosystem. She received her BA from Johns Hopkins, her MS from Georgetown University, her Ph.D. from Thomas Jefferson School of Medicine and completed her postdoctoral fellowship at Harvard Medical School and NIH.

Dr. Agatha Lee serves as the Director of Business Development at the Institute for Follicular Lymphoma Innovation (I-FLI), contributing two decades of expertise in biomedical engineering and distinguished strategic leadership within the biotechnology sector. Her core competencies include drug discovery and development, management of strategic alliances, business development and investment execution, along with considerable experience in clinical trials and operational readiness of GMP manufacture.

Dr. Lee holds a BS in Biomedical Engineering from the Johns Hopkins University and a Ph.D. in Neuroimaging (Biomedical Engineering) from UCLA. After completing her postdoctoral fellowship at UCLA, she advanced into intellectual property and licensing roles within technology transfer offices at several noted institutions, including UCLA, The Henry M. Jackson Foundation (under Department of Defense), and LA Biomed. Dr. Lee later transitioned to the corporate sector, where she served as Vice President of Strategic Alliances at Emmaus Life Sciences, contributing to the development and commercialization of the first FDA-approved treatment for sickle cell disease. Currently, she works at I-FLI, a family office-backed venture capital, focusing on philanthropic investment to advance cures for follicular lymphoma patients.



The Way of Yuhan

Yuhan Corporation, a group loved by the people and grown together with the people
For the last 90 years, the corporate culture of honesty and integrity,
and the strong beliefs in social responsibility are what made Yuhan what it is today.

Looking back on the path that we moved on and thinking of the path ahead,
Yuhan will make the leap as a global pharmaceutical company through innovative new drug development,
and by enabling healthiness and happiness for all the people in the world.

In the next 100 years, Yuhan Corporation will follow the noble spirit of our founder, Dr. New Ilhan,
and write the history of challenge and development moving forward.

Our challenge has already begun.

YUHAN


Dong-A ST
Our goal is to achieve the MOST optimal level of human health.
By improving products that alleviate the burden on patients, we develop the best medicine that all patients can comfortably use.
MOST
We uphold the principles of MUST.
We undertake the essential task of developing new drugs for the treatment of rare and orphan diseases, for the happiness of humanity's future.
We create societal value with what we do best: the development of innovative pharmaceuticals.
Company specializing in prescription drugs
Dong-A ST

SAMYANG BIOPHARM

Accelerating Gene Therapy Development Leveraging
Innovative Tissue-selective Delivery Platform Technology

Partnering Website

About Us

Founded in 1995 as the Pharmaceutical Business Division of Samyang Corporation, Samyang Biopharm has enhanced its competitiveness across medical devices, pharmaceuticals, and new therapeutics, growing into a 'trusted healthcare solutions partner' dedicated to improving the quality of life.

Focus Areas

Medical Device
Global #1 supplier of suture bulk thread (>50%)

- Absorbable surgical suture
- Hemostatic agent and anti-adhesion agent
- Lifting threads, fillers, skin boosters

Modified Drug
World's first bio-polymer nanoparticle applied cytotoxic drugs

- Bio-polymer encapsulated modified drugs
- Cytotoxic anticancer drugs
- Difficult-to-Make generics

SENS™, Selectivity Enabling NanoShell

Proprietary Polymer-Lipid Hybrid Nanoparticles for Nucleic Acid Therapeutics

① **Tissue-selective Targeting**
Achieves efficient ex-hepatic tissue-selective delivery with cell targeting capabilities

② **Superior Delivery Efficiency**
Enables long-term efficacy without anti-drug antibody (ADA) production for chronic treatment

③ **Improved Toxicity**
Improved toxicity enabling safe delivery

④ **Wide Applicability**
Delivers payloads of various sizes (~11kb) and modalities

New Therapeutics Development of Samyang Biopharm

Cell and Gene Therapy
- In vivo CAR-X
- CRISPR/CasX

Protein Replacement
Ab-encoding RNA (AER)

Personalized Medicine
NeoAg anticancer Vaccine

Cell-specific Modality
Active targeting conjugation
- Ab-SENS™
- Tides-SENS™

Symposium Feedback

심포지움 참석에 감사드립니다. 더욱 성공적인 개최를 위하여 개선점, 추가로 다뤄졌으면 하는 토픽이나 건의사항을 좌측 QR code 를 스캔하여 공유해주시면 감사하겠습니다.
Feedback에 응하신 참석자들을 추첨하여 당첨자 2분께 사은품을 증정할 예정입니다 (단, 익명으로 참석하신 분들은 추첨에서 제외됩니다).

Enable connection of talents (people), business, and ideas

KASBP SAN FRANCISCO

www.kasbpsf.org

Sponsors

Platinum Sponsor

LigaChemBio

Gold Sponsors

YUHAN

DONG-A ST

Silver Sponsors

SAMYANG BIOPHARM

AIMEDBIO

주샌프란시스코 대한민국 총영사관
Consulate General of the Republic of Korea in San Francisco

Bronze Sponsors

Hanmi Global · R&D Leader Hanmi Pharm.

GI innovation

GENEDIT

ILDONG

KANAPH Therapeutics Inc.

Fin Therapeutics

I.DIVINE

SK biopharmaceuticals

KASBP SF Committee

Roles	Korean Name	English Name	Affiliation
President	윤오규	OhKyu Yoon	Gilead Sciences
President Team	김상엽	Sang Yeop Kim	Merck
Finance Team	조향	Hyang Jo	Genentech
	이동은	Agatha Lee	IFLI
Science Team	한진환	Jin-Hwan Han	Merck
	김수진	Soojin Kim	Genentech
	이성진	Sungjin Lee	Insitro
	김유미	Yu-mee Kim	Genentech
	조효석	Hyosuk Cho	Sangamo Therapeutics
PR-Membership Team	장아람	Aram Chang	Bristol Myers Squibb
	이현철	Hyuncheol Lee	Vivere Oncotherapies
	김기철	Kicheol Kim	Everest Detection
	김양준	Yangjun Kim	Chan Zuckerberg Biohub
	유권태	KwonTae You	Illumina

KASBP SF Symposium 2025 Attendees

* Early Bird registration Only

	Last Name	First Name	이름	Company / Institution	Networking Group
1	Ahn	Sunny	안선희	Aimed Bio Inc.	6
2	Chae	Jeiwook	채제욱	LigaChem Biosciences	6
3	Cho	Min-Kyu	조민규	GSK	3
4	Cho-Fertikh	Elizabeth	Elizabeth Cho-Fertikh	MEDA Ventures	6
5	Choi	Sofia	최예원	Merck	6
6	Choi	YJ	최연정	Genentech	4
7	Choi	Yongbin	최용빈	Genentech	6
8	Choi	Youngjin	최영진	Dong-A ST	6
9	Chun	Bokhwan	전복환	KDDF	6
10	Chun	Jiwon	전지원	Lotte Biologics	6
11	Chung	Seung Wook	정승욱	Johnson & Johnson	2
12	Fadeyi	Saudat	Saudat Fadeyi	Samyang Biopharm USA Inc.	6
13	Han	Jin-Hwan	한진환	Merck & Co.	7
14	Her	Nam-Gu	허남구	Aimed Bio Inc.	6
15	Hong	JunHo	홍준호	GI INNOVATION	6
16	Hong	Kibeom	홍기범	UCSF	5
17	Hur	Seong kwon	허성권	Genentech	1
18	Hwang	Daeun	황다은	Yuhan USA	1
19	Hwang	Sungyong	황성용	Silver Spring	3
20	Inn	Kyung-Soo	인경수	Prazer Therapeutics	7
21	Jang	Myoung Ho	장명호	GI INNOVATION	6
22	Jeong	Daeyoung	정대영	LigaChem Biosciences	6
23	Jeong	Heykyeong	정혜경	GSK	1
24	Jeong	Jae Uk	정재욱	GC Biopharma Corp.	6
25	Jeong	Ted	정태흠	Adelphi Ventures	6

	Last Name	First Name	이름	Company / Institution	Networking Group
26	Jin	Hyun Yong	진현용	Genentech	2
27	Jo	Hyunsun	조현선	Pin Therapeutics	6
28	Jung	Hyunkyung	정현경	Medic Life Sciences Inc.	1
29	Jung	Inyoung	정인영	Synthekine	6
30	Kang	Jongkyun	강종균	Dong-A ST	1
31	Kang	Min Suk	강민석	Columbia University Irving Medical Center	1
32	Kasmar	Anne	앤 카스마르	Parexel	2
33	Kim	Bonnie	김보연	Tempus AI	2
34	Kim	Ellen Jooyeon	김주연	KDDF	6
35	Kim	Euno	김은오	SK Biopharmaceuticals	1
36	Kim	Heejin	김희진	Prazer Therapeutics	6
37	Kim	JiHyeon	김지현	Stanford University	1
38	Kim	Kelly	Kelly Kim	OliX Pharmaceuticals	6
39	Kim	Kyung	김경효	AbbVie	3
40	Kim	Kyung Jin	김경진	Samyang Biopharmaceutical Corporation	5
41	Kim	Min Joo	김민주	Stanford University	6
42	Kim	Nam Cheol	김남철	USP	3
43	Kim	Sang	김상엽	Merck	1
44	Kim	Sean	김태수	Ice Miller LLP	5
45	Kim	Sehyun	김세현	Merck	6
46	Kim	Soojin	김수진	Genentech	6
47	Kim	Soojin	김수진	Gilead Sciences	3
48	Kim	Sunmi	김선미	ICI	5
49	Kim	Youngmi	김영미	Pfizer	6
50	Kim	Yu-Mee	김유미	Genentech	1
51	Ko	Donggun	고동건	Fresenius-Kabi	3
52	Kwon	Youngsu	권영수	BeOne Medicine	1

	Last Name	First Name	이름	Company / Institution	Networking Group
53	Lee	Agatha	이동은	I-FLi	6
54	Lee	Anthony	이재용	Immunome, Inc	2
55	Lee	BoRam	이보람	Merck	4
56	Lee	Byoung Chul	이병철	Kanaph Therapeutics	6
57	Lee	Donggi	이동기	PhnyX Lab	1
58	Lee	Grace	이호영	Elevalue	5
59	Lee	Heewon	이희원	Daewoong Pharmaceutical Co. Ltd.	1
60	Lee	Kunwoo	이근우	GenEdit	5
61	Lee	Michelle	이지원	Stanford University	1
62	Lee	Narae	이나래	Arcturus Therapeutics	3
63	Lee	Sungjin	이성진	Insitro	1
64	Lee	SungJin	이성진	CVS Health	2
65	Lee	Yejin	이예진	Yuhan USA	6
66	Lee	Youhan	이유한	NVIDIA/BioNeMo	4
67	Lim	Hansol	임한솔	Stanford University	5
68	Lim	JaeHyun	임재현	Rapigen America Inc.	3
69	Lim	Sungwon	임성원	ImpriMed	6
70	Min	Byeongkwi	민병귀	Aimed Bio Inc.	1
71	Moon	Seung Hyun	문승현	Adelphi Ventures	6
72	Nam	Do-Hyun	남도현	Aimed Bio Inc.	2
73	Oh	Jaehak	오재학	Qymune	6
74	Paik	Kwang Il	백광일	SK Biopharmaceuticals	1
75	Park	Daniel	박다니엘	Synthekine	5
76	Park	Goonho	박군호	PathoBrainSeq	6
77	Park	Haeseong	박혜성	LigaChem Biosciences	7
78	Park	Hangil	박한길	Qymune	1
79	Park	Hyo Min	박효민	GenEdit	6

	Last Name	First Name	이름	Company / Institution	Networking Group
80	Park	Jinho	박진호	Seawolf Therapeutics	5
81	Park	Sejin	박세진	LigaChem Biosciences	7
82	Pi	Yeonhee	피연희	Ildong Pharmaceutical Co.LTD / Yunovia	6
83	Rhee	Byung Geon	이병건	GI Innovation	6
84	Seo	Hyeonglim	서형림	Genentech	2
85	Shim	Jeongsup	심정섭	Genentech	2
86	Son	Jiyeon	손지연	GC Biopharma	5
87	Song	Sunny	써니송	Standigm/Hanalladvisors	6
88	Suh	Chris	Chris Suh	Biotage	1
89	Sung	Jongmin	성종민	Addition Therapeutics	4
90	Woo	Sangsoon	우상순	Corcept Therapeutics	4
91	Yang	Hyunjin	양현진	Ubix Therapeutics	6
92	Yang	James	양주성	Samyang Biopharmaceutical Corporation	5
93	Yoo	Justin	유승호	YOUTH BIOTECH	5
94	Yoon	Hayan	윤하얀	Fenwick & West	6
95	Yoon	OhKyu	윤오규	Gilead Sciences	4
96	Yoon	Taewon	윤태원	Yuhan USA Corporation	6
97	You	Dongjoo	유동주	UC Berkeley	7
98	You	Kwontae	유권태	illumina	6
99	Yu	Bohyeon	유보현	University of California, San Francisco (UCSF)	4
100	Yun	Nari	윤나리	GI INNOVATION	6

Networking Groups

	Group	Room
1	Discovery - Early Development of Therapeutics	Atrium
2	Translational and Clinical Research / Biomarker	Atrium
3	CMC & Manufacturing & Late Development of Therapeutics / Regulatory Affairs	Atrium
4	AI&ML / Bioinformatics / Statistics	Atrium
5	Cell & Gene Therapy / Platforms & Enabling Technologies	Atrium
6	Business Development / Venture Capital / Corporate Development	Pople Pavilion
7	Career Development	Boardroom

Hotel Map



Notes

kasbpsf.org

KASBP
SAN FRANCISCO

Sign up for KASBP-SF membership on our website

www.kasbpsf.org

KASBP-SF membership is free.
Receive announcements on upcoming events.